In this study, we analyzed six different breast cancer cohorts aiming to characterize clinicopathological features, epigenetic regulation factors, genomic alterations, and develop gene panel to identify its intrinsic molecular subtypes, which may serve as novel biomarkers or therapeutic targets for grade III ER+HER2− breast cancer patients’ treatments. This evidence concerns the gene ERBB2 and breast cancer.